The R246S hot-spot p53 mutant exerts dominant-negative effects in embryonic stem cells in vitro and in vivo

Journal of Cell Science

Volumn 121, Issue 11, 2008, Pages 1899-1906

  Lee, Ming Kei ^a   Sabapathy, Kanaga ^a,b  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Dominant negative; Embryonic stem cells; Knock in; Mutant p53; R246S

Indexed keywords

CARBON TETRACHLORIDE; PROTEIN P53;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL NUCLEUS; CELL SURVIVAL; CELLULAR DISTRIBUTION; CONTROLLED STUDY; EMBRYO; EMBRYONIC STEM CELL; GENE EXPRESSION; IN VITRO STUDY; IN VIVO STUDY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER INJURY; MOUSE; MUTANT; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; STRESS;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; CARCINOGENICITY TESTS; CARCINOMA, HEPATOCELLULAR; CELL DIFFERENTIATION; CELL TRANSFORMATION, NEOPLASTIC; DNA DAMAGE; EMBRYONIC STEM CELLS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, CDC; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, TRANSGENIC; MUTATION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 46749158345     PISSN: 00219533     EISSN: None     Source Type: Journal    
DOI: 10.1242/jcs.022822     Document Type: Article

References (44)

1. Aurelio, O. N., Kong, X. T., Gupta, S. and Stanbridge, E. J. (2000). p53 mutants have selective dominant-negative effects on apoptosis but not growth arrest in human cancer cell lines. Mol. Cell. Biol. 20, 770-778.
2. Brazel, C. Y., Romanko, M. J., Rothstein, R. P. and Levison, S. W. (2003). Roles of the mammalian subventricular zone in brain development. Prog. Neurobiol. 69, 49-69.
3. Brooks, D. G., James, R. M., Patek, C. E., Williamson, J. and Arends, M. J. (2001). Mutant K-ras enhances apoptosis in embryonic stem cells in combination with DNA damage and is associated with increased levels of pl9(ARF). Oncogene 20, 2144-2152.
4. Chan, W. M., Siu, W. Y., Lau, A. and Poon, R. Y. (2004). How many mutant p53 molecules are needed to inactivate a tetramer? Mol. Cell. Biol. 24, 3536-3551.
5. Chao, C., Saito, S., Anderson, C. W., Appella, E. and Xu, Y. (2000). Phosphorylation of murine p53 at ser- 18 regulates the p53 responses to DNA damage. Proc. Natl. Acad. Sci. USA 97, 11936-11941.
6. Clarke, A. R., Purdie, C. A., Harrison, D. J., Morris, R. G., Bird, C. C., Hooper, M. L. and Wyllie, A. H. (1993). Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362, 849-852.
7. Davis, P., Bazar, K., Huper, G., Lozano, G., Marks, J. and Iglehart, J. D. (1996). Dominance of wild-type p53-mediated transcriptional activation in breast epithelial cells. Oncogene 13, 1315-1322.
8. de Vries, A., Flores, E. R., Miranda, B., Hsieh, H. M., van Oostrom, C. T., Sage, J. and Jacks, T. (2002). Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function. Proc. Natl. Acad Sci. USA 99, 2948-2953.
9. Fenoglio-Prelser, C. M., Wang, J., Stemmermann, G. N. and Noffisinger, A. (2003). TP53 and gastric carcinoma: a review. Hum. Mutat. 21, 258-270.
10. Forslund, A., Kressner, U., Lonnroth, C., Andersson, M., Lindmark, G. and Lundholm, K. (2002). P53 mutations in colorectal cancer assessed in both genomic DNA and cDNA as compared to the presence of p53 LOH. Int. J. Oncol. 21, 409-415.
11. Ghebranious, N. and Sell, S. (1998). Hepatitis B injury, mate gender, aflatoxin, and p53 expression each contribute to hepatocarcinogenesis in transgenic mice. Hepatology 27, 383-391.
12. Ghebranious, N., Knoll, B. J., Wu, H., Lozano, G. and Sell, S. (1995). Characterization of a routine p53ser246 mutant equivalent to the human p53ser249 associated with hepatocellular carcinoma and aflatoxin exposure. Mol. Carcinog. 13, 104-111.
13. Harvey, M., Vogel, H., Morris, D., Bradley, A., Bernstein, A. and Donehower, L. A. (1995). A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53-deficient mice. Nat. Genet. 9, 305-311.
14. Hayday, A. C. and Pennington, D. J. (2007). Key factors in the organized chaos of early T cell development. Nat. Immunol. 8, 137-144.
15. Hulla, J. E., Chen, Z. Y. and Eaton, D. L. (1993). Aflatoxin B1-induced rat hepatic hyperplastic nodules do not exhibit a site-specific mutation within the p53 gene. Cancer Res. 53, 9-11.
16. Jacks, T., Remington, L., Williams, B. O., Schmitt, E. M., Halachmi, S., Bronson, R. T. and Weinberg, R. A. (1994). Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 4, 1-7.
17. Jackson, E. L., Olive, K. P., Taveson, D. A., Bronson, R., Crowley, D., Brown, M. and Jacks, T. (2005). The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res. 65, 10280-10288.
18. Lang, G. A., Iwakuma, T., Suh, Y. A., Liu, G., Rao, V. A., Parant, J. M., Valentin-Vega, Y. A., Terzian, T., Caldwell, L. C., Strong, L. C. et al. (2004). Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumem syndrome. Cell 119, 861-872.
19. Lee, M. K., Hande, M. P. and Sabapathy, K. (2005). Ectopic mTERT expression in mouse embryonic stem cells does not affect differentiation but confers resistance to difterentiation- and stress-induced p53-dependent apoptosis. J. Cell Sci. 118, 819-829.
20. Li, D., Cao, Y., He. L., Wang, N. J. and Gu, J. R. (1993). Aberrations of p53 gene in human hepatocellular carcinoma from China. Carcinogenesis 14, 169-173.
21. Luo, J. L., Yang, Q., Tong, W. M., Hergenhahn, M., Wang, Z. Q. and Hollstein, M. (2001). Knock-in mice with a chimeric hurnan/murine p53 gene develop normally and show wild-type p53 responses to DNA damaging agents: a new biomedical research tool. Oncogene 20, 320-328.
22. Martins, C., Kedda, M. A. and Kew, M. C. (1999). Characterization of six tumor suppressor genes and microsatellite instability in hepatocellular carcinoma in southern African blacks. World J. Gastroenterol. 5, 470-476.
23. Meletis, K., Wirta, V., Hede, S. M., Nister, M., Lundeberg, J. and Frisen, J. (2006). p53 suppresses the self-renewal of adult neural stem cells. Development 133, 363-369.
24. Mendrysa, S. M., McElwee, M. K., Michalowski, J., O'Leary, K. A., Young, K. M. and Perry, M. E. (2003). mdm2 Is critical for inhibition ofp53 during lymphopoiesis and the response to ionizing irradiation. Mol. Cell. Biol. 23, 462-472.
25. Nishida, N., Fukuda, Y., Kokuryu, H., Toguchida, J., Yandell, D. W., Ikenega, M., Imura, H. and Ishizaki, K. (1993). Role and mutational heterogeneity of the p53 gene in hepatocellular carcinoma. Cancer Res. 53, 368-372.
26. Oda, T., Tsuda, H., Scarps, A., Sakamoto, M. and Hirohashi, S. (1992). p53 gene mutation spectrum in hepatocellular carcinoma. Cancer Res. 52, 6358-6364.
27. Oda, T., Tsuda, H., Sakamoto, M. and Hirohashi, S. (1994). Different mutations of the p53 gene in nodule-in-nodule hepatocellular carcinoma as a evidence for multistage progression. Cancer Lett. 83, 197-200.
28. Olive, K. P., Tuveson, D. A., Ruhe, Z. C., Yin, B., Willis, N. A., Bronson, R. T., Crowley, D. and Jacks, T. (2004). Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119, 847-860.
29. Olivier, M., Hussain, S. P., Caron de Fromental, C., Hainaut, P. and Harris, C. C. (2004). TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer. IARC Sci. Publ. 2004, 247-270.
30. Oren, M. (1992). p53: the ultimate tumor suppressor gene? FASEB J. 6, 3169-3176.
31. Peng, X. M., Peng, W. W. and Yao, J. L. (1998). Codon 249 mutations of p53 gene in development of hepatocellular carcinoma. World J. Gastroenterol. 4, 125-127.
32. Petitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S. V., Hainaut, P. and Olivier, M. (2007). Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum. Mutat. 28, 622-629.
33. Sabapathy, K., Klemm, M., Jaenisch, R. and Wagner, E. F. (1997). Regulation of ES cell differentiation by functional and conformational modulation of p53. EMBO J. 16, 6217-6229.
34. Soussi, T. (2000). The p53 tumor suppressor gene: from molecular biology to clinical investigation. Ann. N. Y. Acad Sci. 910, 121-137.
35. Staib, F., Hussain, S. P., Hofseth, L. J., Wang, X. W. and Harris, C. C. (2003). TP53 and liver carcinogenesis. Hum. Mutat. 21, 201-216.
36. Tong, W. M., Lee, M. K., Galendo, D., Wang, Z. Q. and Sabapathy, K. (2006). Aflatoxin-B exposure does not lead to p53 mutations but results in enhanced liver cancer of Hupki (human p53 knock-in) mice. Int. J. Cancer 119, 745-749.
37. Varley, J. M., Thorncroft, M., McGown, G., Appleby, J., Kelsey, A. M., Tricker, K. J., Evans, D. G. and Birch, J. M. (1997). A detailed study of loss of heterozygosity on chromosome 17 in tumours from Li-Fraumeni patients carrying a mutation to the TP53 gene. Oncogene 14, 865-871.
38. -/- mouse model in carcinogenicity testing. Toxicol. Pathol. 29 Suppl, 147-154.
39. Vikhanskaya, F., Lee, M. K., Mazzoletti, M., Broggini, M. and Sabapathy, K. (2007). Cancer-derived p53 mutants suppress p53-target gene expression-potential mechanism for gain of function of mutant p53. Nucleic Acids Res. 35, 2093-2104.
40. Vausden, K. H. and Lu, X. (2002). Live or let die: the cell's response to p53. Nat. Rev. Cancer 2, 594-604.
41. Wijnhoven, S. W., Speksanjder, E. N, Liu, X., Zwart, E., vanOostrom, C. T., Beems, R. B., Hoogervorst, E. M., Schaap, M. M., Attardi, L. D., Jacks, T. et al. (2007). Dominant-negative but not gain-of-function effects of a p53.R270H mutation in mouse epithelium tissue after DNA damage. Cancer Res. 67, 4648-4656.
42. Williams, A. C., Miller, J. C., Collard, T. J., Bracey, T. S., Cosulich, S. and Paraskeva, C. (1995). Mutant p53 is not fully dominant over endogenous wild type p53 in a colorectal adenoma cell line as demonstrated by induction of MDM2 protein and retention of a p53 dependent G1 arrest after gamma irradiation. Oncogene 11, 141-149.
43. Willis, A., Jung, E. J., Wakefield, T. and Chen, X. (2004). Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes. Oncogene 23, 2330-2338.
44. Yamamoto, H., Quinn, G., Asari, A., Yamanokuchi, H., Teratani, T., Terada, M. and Ochiya, T. (2003). Differentiation of embryonic stem cells into hepatocytes: biological functions and therapeutic application. Hepatology 37, 983-993.